T-cell Therapy Market 2023: Industry Drivers, Growth Factors, Regions and Forecast by 2028

Comments · 27

T-cell refers to a form of immunotherapy that involves the use of the patient’s own immune cells to treat cancer.

According to IMARC Group latest report titled T-cell Therapy Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028, offers a comprehensive analysis of the industry, which comprises insights onT-cell therapy marketsegments. The report also includes competitor and regional analysis, and contemporary advancements in the global market. Theglobal T-cell therapy market is expected to exhibit a growth rate (CAGR) of 16.3% during 2023-2028.

What is T-cell?

T-cell is an important part of the immune system and develops from bone marrow stem cells. It helps protect the body from infection and may help fight cancer. T-cell therapy is a procedure to get immune cells to fight cancer by changing them in the laboratory so they can find and kill cancer cells. It involves changing the genes inside T cells to help them fight cancer. It is very helpful in treating some types of cancer. It is also FDA-approved to treat several hematological malignancies, including leukemia, lymphoma, and multiple myeloma. T-Cell Therapy is also utilized to enhance the immune response against cancerous cells.

Request to Get the Sample Report:https://www.imarcgroup.com/t-cell-therapy-market/requestsample

What are the growth prospects and trends in the T-cell industry?

The global market is majorly driven by the increasing demand for ideal therapeutics for the treatment of cancer. In line with this, the rising prevalence of cancer worldwide is significantly contributing to market growth. Furthermore, the favorable reimbursement policies in several countries regarding CAR T-cell therapy are positively influencing the market. Apart from this, the growing incidences of lymphoma and leukemia are catalyzing the market. Moreover, the escalating approvals coupled with expanding manufacturing capabilities are propelling the market expansion. Besides, the heavy investments in research and development activities by the market players are favoring the market. Additionally, the increasing number of relapsed or refractory cancer cases showing response failure to alternative treatments such as chemotherapy and radiation therapy is providing a boost to the market.

Explore Full Report with Table of Contents:https://www.imarcgroup.com/t-cell-therapy-market

Competitive Landscape:

The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.

  • Amgen Inc.
  • Aurora Biopharma Inc.
  • bluebird bio Inc
  • Bristol-Myers Squibb Company
  • Fate Therapeutics
  • Gilead Sciences Inc.
  • Merck KGaA
  • Mustang Bio Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sorrento Therapeutics Inc.
  • TCR2 Therapeutics

T-cell Therapy Market Segmentation:

Our report has categorized the market based on region, modality, therapy type and indication.

Breakup by Modality:

  • Research
  • Commercialized

Breakup by Therapy Type:

  • CAR T-cell based
  • T Cell Receptor (TCR) based
  • Tumor Infiltrating Lymphocytes (TIL) based

Breakup by Indication:

  • Hematologic Malignancies
    • Lymphoma
    • Leukemia
    • Myeloma
  • Solid Tumors
    • Melanoma
    • Brain and Central Nervous System
    • Liver Cancer
    • Others
  • Others

Breakup by Region:

  • North America (United States, Canada)
  • Europe (Germany, France, United Kingdom, Italy, Spain, Others)
  • Asia Pacific (China, Japan, India, Australia, Indonesia, Korea, Others)
  • Latin America (Brazil, Mexico, Others)
  • Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Other)

Key highlights of the report:

  • Market Performance (2017-2022)
  • Market Outlook (2023-2028)
  • Porters Five Forces Analysis
  • Market Drivers and Success Factors
  • SWOT Analysis
  • Value Chain
  • Comprehensive Mapping of the Competitive Landscape

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARCs information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the companys expertise.

Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: [email protected]
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe:- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800

Comments